Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues
Reexamination Certificate
2005-02-08
2005-02-08
Kunz, Gary (Department: 1647)
Chemistry: natural resins or derivatives; peptides or proteins;
Proteins, i.e., more than 100 amino acid residues
Reexamination Certificate
active
06852838
ABSTRACT:
The present invention provides for a gene, designated as musk, that encodes a novel tyrosine kinase receptor expressed in high levels in denervated muscle. The invention also provides for an isolated polypeptide which activates MuSK receptor. The invention further provides for a polypeptide which is functionally equivalent to the MuSK activating polypeptide. The invention also provides assay systems that may be used to detect and/or measure ligands that bind the musk gene product. The present invention also provides for diagnostic and therapeutic methods based on molecules that activate MuSK.
REFERENCES:
Rupp F, et al. J. Neuroscience 12(9):3535-3544, 1992.*
The Journal of Neuroscience, vol. 12, No. 9, Sep. 1992, pp. 3535-3544, Rupp, F., et al.: Structure and Chromosomal Localization of the Mammalian Agrin Gene.
EMBL Database, Apr. 22, 1995, Heidelberg, Hillier, L., et al.: “The WashU-Merck EST project, AC R12830.”
EMBL Database, Oct. 7, 1995, Heidelberg, Jay, P.: “Human cDNAs from HE6W library, AC H58758.”
NEURON, vol. 8, No. 6, Jun. 1992, pp. 1079-1086, Ferns, M., et al.: “RNA Splicing Regulates Agrin-Mediated Acetylcholine Receptor Clustering Activity on Cultured Myotubes.”
NEURON, vol. 15, No. 3, Sep. 1995, pp. 573-584, Valenzuela, D., et al., “Receptor Tyrosine Kinase Specific for the Skeletal Muscle Lineage: Expression in Embryonic Muscle, at the Neuromuscular Junction, and after Injury.”
NEURON, vol. 16, Apr. 1996, pp. 755-767, Gesemann, et al.: “Alternative Splicing of Agrin Alters in Binding to Heparin, Dystroglycan, and the Putative Agrin Receptor.”
The EMBO Journal, vol. 13, No. 12, 1994, pp. 2814-2821, Hoch, W., et al.: “Structural domains of agrin required for clustering of nicotinic acetylcholine receptors.”
The EMBO Journal, vol. 15., No. 11, pp. 2625-2631, Meier, T., et al.: “AChR phosphorylation and aggregation induced by an agrin fragment that lacks the binding domain for α-dystroglycan.”, 1996.
The Journal of Cell Biology, vol. 128, No. 4, Feb. 1995, pp. 625-636, Gesemann, M., “Acetylcholine Receptor-aggregating Activity Of Agrin Isoforms and Mapping of the Active Site.”
The Journal of Cell Biology, vol. 128, No. 6, Mar. 1995, pp. 1121-1129, Wallace, B.: “Regulation of the interaction of nicotinic acetylcholine receptors with the cytoskeleton by agrin-activated protein tyrosine kinase.”
Annual Reviews in Neuroscience, vol. 18, 1995, pp. 443-462, Bowe, M. and Fallon, J.: “The Role Of Agrin in Synapse Formation.”
CELL, vol. 85, No. 4, May 17, 1996, pp. 513-523, Glass, D., et al.: “Agrin Acts via a MuSK Receptor Complex.”
Bowen David C.
Glass David J.
Valenzuela David M.
Yancopoulos George D.
Kunz Gary
Landsman Robert
Regeneron Pharmaceuticals Inc.
Valeta Gregg, Esq.
LandOfFree
Tyrosine kinase receptors and ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Tyrosine kinase receptors and ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Tyrosine kinase receptors and ligands will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3502583